Evidence map›Paper›PMID 38299030›Full record

ArticleiScience2024

VentX promotes tumor specific immunity and efficacy of immune checkpoint inhibitors.

Yi Le, Hong Gao, Joanna Le, Jason L Hornick, Ronald Bleday, Jon Wee, Zhenglun Zhu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yi LeDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Hong GaoDepartment of Medicine, Tufts Medical Center, Boston, MA, USA.
Joanna LeDepartment of Obstetrics and Gynecology, University of Massachusetts Medical Center.
Jason L HornickDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Ronald BledayDepartment of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Jon WeeDepartment of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Zhenglun ZhuDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Brigham and Women's Hospital · USTufts Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune suppression within tumor microenvironments (TME) have been implicated in limited efficacy of immune check point inhibitors (ICIs) against solid tumors. Down-regulated VentX expression in tumor associated macrophages (TAMs) underlies phagocytotic anergic phenotype of TAMs, which govern immunological state of TME. In this study, using a tumor immune microenvironment enabling model system (TIME-EMS) of non-small cell lung cancer (NSCLC), we found that PD-1 antibody modestly activates cytotoxic T lymphocytes (CTLs) within the NSCLC-TME but not the status of TIME. We showed that the restoration of VentX expression in TAMs reignites the phagocytotic function of TAMs, which in turn, transforms TIME, activates CTLs in a tumor-specific manner and promotes efficacy of PD-1 antibody against NSCLC but not toxicity on normal lung epithelial cells. Supported by

Indexed as

CancerImmunologyMolecular biology

Identifiers

PMID38299030
PMCPMC10829883
OpenAlexW4389736358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.